---
title: "Nxera Pharma swings to FY26 H1 net profit of JPY 1.59 billion; revenue rises to JPY 18.91 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295189063.md"
description: "Nxera Pharma reported a swing to a JPY 1.59 billion net profit for FY26 H1, up from a prior loss, with revenue rising to JPY 18.91 billion. Operating profit turned positive at JPY 1.88 billion due to reduced R&D and SG&A expenses. Cash equivalents decreased to JPY 17.75 billion. Key updates included increased Japan sales of PIVLAZ and QUVIVIQ, South Korea fast-track designations for vamorolone, and milestone payments from partners like AbbVie and Lilly."
datetime: "2026-08-07T06:30:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295189063.md)
  - [en](https://longbridge.com/en/news/295189063.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295189063.md)
generator: "portal-rs"
---

# Nxera Pharma swings to FY26 H1 net profit of JPY 1.59 billion; revenue rises to JPY 18.91 billion

-   Nxera Pharma posted revenue of JPY 18.91 billion for the six months ended June 30, up JPY 3.82 billion from the prior corresponding period. \* Operating profit turned to JPY 1.88 billion from an operating loss of JPY 2.76 billion; net profit swung to JPY 1.59 billion from a net loss of JPY 3.14 billion. \* R&D expenses fell JPY 1.47 billion to JPY 6 billion on maturation of several clinical programs; SG&A decreased JPY 612 million to JPY 6.95 billion on cost cuts. \* Cash and cash equivalents slipped JPY 2.62 billion from fiscal year-end to JPY 17.75 billion. \* First-half updates included rising Japan sales of PIVLAZ and QUVIVIQ, South Korea fast-track designations for vamorolone, and milestone payments from AbbVie, Lilly, Neurocrine and the Centessa collaboration. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070230PRIMZONEFULLFEED1001256493) on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [4565.JP](https://longbridge.com/en/quote/4565.JP.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [NBIX.US](https://longbridge.com/en/quote/NBIX.US.md)
- [CNTA.US](https://longbridge.com/en/quote/CNTA.US.md)

## Related News & Research

- [Nxera Pharma to receive USD 8.6 million milestone payment from Centessa](https://longbridge.com/en/news/297870158.md)
- [Benjamin Edwards Inc. Has $34.94 Million Stake in Eli Lilly and Company $LLY](https://longbridge.com/en/news/298002862.md)
- [W1M Asset Management Ltd Acquires Shares of 5,460 AbbVie Inc. $ABBV](https://longbridge.com/en/news/297755003.md)
- [Eli Lilly's Taltz-Zepbound Combo Shows Encouraging Results At Week 52](https://longbridge.com/en/news/297510647.md)
- [Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.](https://longbridge.com/en/news/297565544.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**